Looking beyond imatinib: next line of targeted drugs for CML shows promise

JAMA. 2006 Jan 25;295(4):369-70. doi: 10.1001/jama.295.4.369.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Dasatinib
  • Drug Resistance, Neoplasm
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Thiazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • nilotinib
  • Dasatinib